公司概述
Tonix Pharmaceuticals Holding Corp. operates as a fully integrated biopharmaceutical entity dedicated to the development and commercialization of therapies targeting central nervous system disorders, immunology, immuno-oncology, infectious diseases, and rare diseases within the United States market. The company functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, which implies a focus on research-intensive innovation and high regulatory standards for product approval. As of the latest data, the organization employs 142 individuals and maintains a total market capitalization of $185.24M while reporting an annual revenue of $13.11M. These valuation and revenue figures indicate that the company currently holds a small-cap profile, suggesting it is in a stage where revenue generation is still scaling relative to its operational costs, a common characteristic for biotechnology firms in the early-to-mid phases of product commercialization.
财务健康
The company reported a revenue of $13.11M over the trailing twelve months, yet it recorded a net income of $-124,021,000 and an EBITDA of $-123,778,000, revealing a significant structural gap where operating expenses substantially exceed total revenue. This disparity highlights a cost structure heavily weighted toward research, development, and commercialization activities rather than immediate profit generation, which is typical for the biotech sector but critical for assessing burn rates. The company generated a free cash flow of $-59,429,000, indicating a continuous consumption of cash resources that limits immediate financial flexibility without external capital raises or asset monetization. Marginal performance is further detailed by a gross margin of 49.3%, which reflects the pricing power and cost of goods sold in the manufacturing phase, contrasted sharply by an operating margin of -895.8% and a profit margin of 0.0%, signaling that overhead costs are currently multiple times the level of revenue. On the balance sheet, Tonix holds $207.64M in cash against only $1.31M in debt, resulting in a debt-to-equity ratio of 0.53, which suggests a relatively conservative leverage position despite the lack of profitability. The current ratio stands at 7.42, demonstrating an exceptionally strong ability to cover short-term obligations with liquid assets. However, return metrics such as a return on equity of -64.5% and a return on assets of -35.7% reveal that management is currently utilizing the company's capital base to generate losses rather than positive returns on investment.
估值评估
Valuation multiples for the company present a mixed picture due to the absence of traditional profitability metrics; the trailing P/E ratio is listed as N/A, while the forward P/E is calculated at -2.53, implying that the market prices the stock based on future expectations of earnings turnaround rather than current profitability. The price-to-book ratio is 0.68, indicating that the market values the company's equity at a discount to its book value, which often occurs in capital-intensive biotechnology firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 14.13 and an EV/EBITDA of 0.26 suggest that investors are willing to pay a significant premium relative to sales, despite the negative earnings multiple. The stock price has fluctuated significantly within the last year, trading between a 52-week high of $69.97 and a 52-week low of $11.60, providing a wide range of volatility for market participants. The beta value of 1.76 indicates that the stock's price volatility is substantially higher than the broader market, moving with greater intensity than the S&P 500 during periods of market stress or rally.
Growth & Income
Revenue growth for the trailing twelve months reached an impressive 108.8% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses. This divergence implies that the company is prioritizing top-line expansion and market penetration over immediate earnings accretion, a strategy that relies on future product approvals or sales milestones to eventually convert revenue into profit. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and cash reserves are being retained and reinvested into growth initiatives rather than distributed to shareholders. Consequently, the overall growth and income profile is defined by aggressive expansion in revenue streams with zero current income distribution, placing the total reliance on capital appreciation for investor returns.